Headquartered in Irvine, CA Fiscal year ends December NYSE: EW edwards.com
Edwards Lifesciences is a medical device company focused exclusively on structural heart disease. It reports sales across three product groups.
- **Transcatheter Aortic Valve Replacement (TAVR):** the SAPIEN platform, including SAPIEN 3 Ultra RESILIA. This is its largest business.
- **Transcatheter Mitral and Tricuspid Therapies (TMTT):** the PASCAL transcatheter edge-to-edge repair system (including PASCAL Ace with Capture Clarity and PASCAL Precision), the EVOQUE tricuspid valve replacement system, and the SAPIEN M3 transcatheter mitral valve replacement system. TMTT sales also include revenue related to Implantable Heart Failure Management.
- **Surgical:** surgical heart valves built on RESILIA tissue, the AUTUS pediatric pulmonary valve, and the ECLIPTIS surgical left atrial appendage system.
Edwards sells to hospitals in the United States, Europe, Japan and the rest of the world, with the U.S. representing the majority of sales. Its strategy centers on clinical evidence generation through trials such as PROGRESS, EARLY TAVR, CLASP IITR, TRISCEND II and ENCIRCLE, which aim to expand indications and reimbursement access. The company sold its Critical Care business in 2025 and now operates as a pure-play structural heart company. Updated
Mitral and tricuspid therapy sales jumped 44.3% year over year, enough for management to lift full-year sales growth guidance and adjusted EPS targets. The structural heart franchise is widening its lead on a crowding field.
We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our businesses and regions, giving us the confidence to raise our full-year outlook.
A guidance raise from the structural heart leader lands while Abbott and Boston Scientific push harder into valve repair, and the growth came from every business and region. The $57 billion medtech name is defending share.
As I reflect on 2026 so far, I am proud of what our teams have accomplished and how we are positioning Edwards for strong, sustainable growth over the long term.
The CEO is steering investors toward the long game just as Boston Scientific pours $1.5 billion into the heart valve fight, and the $57 billion medtech leader has ticked up slightly since he said it. What matters next is whether third quarter structural heart growth backs up that confidence.
Edwards Lifesciences cleared its July 6 ceiling by a hair at $95.20, a fresh 52-week high for the $54.8 billion heart valve maker. The stock has climbed back from $78 in February without a new peak until now.
A 4.98% intraday drop to $88.67 is an outsized single-session move for a $51 billion medical-device name that rarely swings this hard. No confirmed catalyst yet, so watch whether the $93.31 open gets reclaimed.
Pre-Market Stock Futures: Futures are trading higher as we reach the midpoint of the trading week, after the Democrats won a stunning midterm victory, capturing both the House and the Senate. After…
Edwards Lifesciences (NYSE: EW | EW Price Prediction) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market. Edwards doubled down…
Pre-Market Futures: The futures are trading higher this morning after another stellar day across Wall Street on Tuesday, as all the major indices once again ended higher and continue to print new…
South Korea’s National Pension Fund (NPF) is the world’s third-largest pension fund by total assets. It manages 1,185.2 trillion South Korean won ($817 billion). NPF was created by the National Pension Service…
Wednesday's top analyst upgrades and downgrades included AMC Entertainment, Bumble, Comerica, Dell Technologies, Edwards Lifesciences, Etsy, Fisker, Luminar Technologies, Micron Technology, Opendoor Technologies, Pinterest and Snap.
Wednesday's top analyst upgrades and downgrades included Alphabet, Bank of America, Dollar General, Edwards Lifesciences, Fortinet, Fox, Halliburton, LyondellBasell Industries, Paramount Global, SoFi Technologies and Truist Financial.
Wednesday's top analyst upgrades and downgrades included Array Technologies, Conagra Brands, Costco Wholesale, Edwards Lifesciences, Estee Lauder, General Electric, General Mills, Hanesbrands, JPMorgan Chase, Lumen Technologies, Royal Caribbean Cruise, Schlumberger, State Street,…
Friday’s additional top analyst upgrades and downgrades were on Axalta Coating Systems, Caterpillar, DigitalOcean, Edwards Lifesciences, First Solar, Gilead Sciences, Intel, Stanley Black & Decker, Unity Software, Western Union and more.
Thursday's top analyst upgrades and downgrades included Abbott Laboratories, Biohaven, Edwards Lifesciences, Enphase Energy, Halliburton, Invesco, Liberty Energy, Mattel, Netflix, Permian Resources, Range Resources, Roblox, Synchrony Financial and Visa.
Wednesday's top analyst upgrades and downgrades included APA, Edwards Lifesciences, Enterprise Products Partners, Global Payments, International Paper, Johnson & Johnson, Match, Medtronic, Netflix, Trade Desk, UDR and Walmart.
Tuesday's top analyst upgrades and downgrades included Adobe, Cheniere Energy, CNX Resources, Edwards Lifesciences, EOG Resources, Huntsman, Kraft Heinz, NCR, Peloton Interactive, PulteGroup, Take-Two Interactive Software and UDR.
Wednesday afternoon's top analyst upgrades and downgrades included Acadia Pharmaceuticals, Constellation Energy, Edwards Lifesciences, Host Hotels & Resorts, Johnson & Johnson and Magna International.
Thursday's top analyst upgrades and downgrades included Advanced Micro Devices, Beyond Meat, Colgate-Palmolive, Edwards Lifesciences, Electronic Arts, Exxon Mobil, Meta Platforms, PayPal and Starbucks.
After a good start on Wednesday, markets sank in the afternoon. Thursday's opening was indicated to be mixed.
Thursday’s top analyst upgrades and downgrades included Airbnb, Citigroup, Edwards Lifesciences, Huntsman, KeyCorp, McDonald's, Netflix, Peloton, Southwest Airlines, Starbucks, Twitter, Under Armour, UPS and Walt Disney.
Edwards Lifesciences is a medical device company focused exclusively on structural heart disease. It reports sales across three product groups. - **Transcatheter Aortic Valve Replacement (TAVR):** the SAPIEN platform, including SAPIEN 3 Ultra RESILIA.
24/7 Wall St.'s 12-month price target for EW is $89.94, rated Hold. The Wall Street consensus target is $101.87. EW price prediction →
